中国肺癌杂志2026，Vol.29Issue(1)：35-46,12.DOI:10.3779/j.issn.1009-3419.2026.106.01
晚期NSCLC一线免疫治疗合适的持续时间及其预测因素
Appropriate Duration of First-line Immunotherapy for Advanced NSCLC and Predictive Factors
摘要
Abstract
First-line immunotherapy for advanced non-small cell lung cancer(NSCLC)shows significant survival benefits in patients without driver mutations,but the optimal duration of treatment remains controversial.Some studies sup-port limiting immunotherapy to 2 years,arguing that longer treatment does not bring additional survival benefits;while other studies believe that treatment should continue until disease progression to maximize survival benefits.This article systemati-cally reviews the current research progress on the duration of immunotherapy and discusses the potential predictive value of biomarkers such as circulating tumor DNA(ctDNA),the best efficacy response,and programmed cell death ligand 1(PD-L1)expression levels in individualized treatment decisions.More prospective studies,especially biomarker-driven trials,are still needed to clarify the optimal duration of treatment and establish an individualized treatment strategy based on multidimen-sional indicators.关键词
肺肿瘤/免疫治疗/治疗持续时间/ctDNA/疗效反应/PD-L1Key words
Lung neoplasms/Immunotherapy/Treatment duration/ctDNA/Efficacy response/PD-L1引用本文复制引用
殷越,郭小僮,艾婧,岳继博,邓立力..晚期NSCLC一线免疫治疗合适的持续时间及其预测因素[J].中国肺癌杂志,2026,29(1):35-46,12.基金项目
This paper was supported by the grants from Wu Jieping Medical Foundation(No.320.6750.2022-18-36,to Lili DENG （）
No.320.6750.2023-17-10,to Lili DENG). 本文受吴阶平医学基金会项目(No.320.6750.2022-18-36,No.320.6750.2023-17-10)资助 （No.320.6750.2022-18-36,No.320.6750.2023-17-10）
